FY2024 EPS Estimates for Alumis Lowered by Leerink Partnrs

Alumis Inc. (NASDAQ:ALMS) – Investment analysts at Leerink Partnrs decreased their FY2024 earnings per share (EPS) estimates for Alumis in a report issued on Wednesday, November 13th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($9.55) per share for the year, down from their prior forecast of ($8.13). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Alumis’ current full-year earnings is ($7.98) per share. Leerink Partnrs also issued estimates for Alumis’ Q4 2024 earnings at ($1.34) EPS, FY2025 earnings at ($5.19) EPS, FY2026 earnings at ($5.52) EPS, FY2027 earnings at ($6.54) EPS and FY2028 earnings at ($4.04) EPS.

A number of other research analysts also recently issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Alumis in a research report on Thursday, November 14th. Robert W. Baird started coverage on Alumis in a research note on Thursday, October 31st. They issued an “outperform” rating and a $25.00 target price on the stock. Morgan Stanley assumed coverage on Alumis in a research report on Tuesday, July 23rd. They set an “overweight” rating and a $36.00 price target for the company. HC Wainwright lowered their price objective on Alumis from $30.00 to $26.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Finally, Baird R W raised shares of Alumis to a “strong-buy” rating in a report on Thursday, October 31st. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $26.83.

Alumis Stock Down 2.4 %

Shares of NASDAQ ALMS opened at $8.64 on Monday. The company’s 50 day simple moving average is $11.22. Alumis has a 12 month low of $8.23 and a 12 month high of $13.53.

Institutional Investors Weigh In On Alumis

Institutional investors have recently added to or reduced their stakes in the stock. Towerview LLC acquired a new position in shares of Alumis during the 2nd quarter worth about $4,123,000. SR One Capital Management LP acquired a new position in shares of Alumis during the second quarter valued at approximately $26,067,000. Ally Bridge Group NY LLC purchased a new position in shares of Alumis in the second quarter valued at approximately $8,229,000. Yu Fan acquired a new stake in shares of Alumis in the second quarter worth approximately $10,502,000. Finally, Millennium Management LLC purchased a new stake in shares of Alumis during the second quarter worth approximately $3,376,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.